Matrix Metalloproteinase Activated Multimodal 'Theranostic' Drug Delivery Imaging Agents For Thrombosis

Dr Simon Calaminus S.Calaminus@hull.ac.uk
Senior Lecturer

Professor David Allsup D.J.Allsup@hull.ac.uk
Professor of Haematology

Dr Jean-Sebastien Bouillard J.Bouillard@hull.ac.uk
Senior Lecturer in Physics and Nanotechnology

ThrombiGlow: ‘Smart’ Multimodal Platelet Specific ‘Theranostic’ Drug Delivery Imaging Feb 1, 2017 - Jan 31, 2020
Cardiovascular diseases (CVD) including heart attacks and strokes constitute the leading cause of mortality in the UK. The pathology underlying CVD is called atherothrombosis and is a complex, multi-cellular-inflammatory disorder. Central to this is... Read More about ThrombiGlow: ‘Smart’ Multimodal Platelet Specific ‘Theranostic’ Drug Delivery Imaging.

LIPS: A prospective registry-based cohort study to monitor the diagnosis and management of acute leukaemia in pregnancy Jun 1, 2018 - Feb 28, 2022
Acute leukaemia (AL) is an aggressive but potentially curable cancer that can affect women of childbearing age. When a pregnancy is complicated by a diagnosis of AL, clinicians face a complex dilemma: to balance risking the mother’s survival through... Read More about LIPS: A prospective registry-based cohort study to monitor the diagnosis and management of acute leukaemia in pregnancy.

CLL Research Jan 26, 2015 - Dec 31, 2028
Translational research project utilising prospective sample collection from patients attending the Haematology Clinic, Hull university Teaching Hospital Trust, to facilitate research within the University of Hull.

Platelet cAMP signalling controls thrombosis through enhanced embolisation Oct 1, 2015 - Sep 30, 2018
The activation of protein kinase A (PKA) by prostacyclin inhibits platelet activation and therefore modulates arterial thrombosis. However, the role of PKA in controlling the stability of pre-existing thrombi is unclear. The stability of thrombi is r... Read More about Platelet cAMP signalling controls thrombosis through enhanced embolisation.

STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL) Jan 1, 2021 - Mar 31, 2031
Chronic lymphocytic leukaemia (CLL) is a cancer that affects the blood and bone marrow. It tends to progress slowly, and is incurable. CLL is the most common leukaemia in adults. The first treatment for CLL is chemotherapy. This is usually given for... Read More about STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL).